Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

incomplete Freund's adjuvant

Phase 3Biologic

EEastern Cooperative Oncology Group

Incomplete Freund's adjuvant is used in research settings to boost the immune system's response to vaccines and experimental treatments, helping scientists test how well new medicines work.[1] incomplete Freund's adjuvant is currently being investigated across 17 indications[3], with its most advanced program in Phase 3.[1]

incomplete Freund's adjuvant is one of 457 biologic programs targeting Prostate Adenocarcinoma. It is currently in Phase 3.

17

Indications

53

Total Trials

2

Active Trials

456

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate AdenocarcinomaActive, not recruiting

Lung CancerActive, not recruiting

Cutaneous MelanomaActive, not recruiting

Metastatic MelanomaActive, not recruiting

Neuroendocrine CarcinomaActive, not recruiting

Ovarian NeoplasmActive, not recruiting

Fallopian Tube CancerActive, not recruiting

Plasmodium Vivax MalariaActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Prostate AdenocarcinomaPhase 2

Active, not recruiting

Lung CancerPhase 2

Active, not recruiting

Cutaneous MelanomaPhase 3

Active, not recruiting

Metastatic MelanomaPhase 2

Active, not recruiting

Neuroendocrine CarcinomaPhase 2

Active, not recruiting

Ovarian NeoplasmPhase 2

Active, not recruiting

Fallopian Tube CancerPhase 1

Active, not recruiting

Plasmodium Vivax MalariaPhase 1

Active, not recruiting

Myelodysplastic SyndromePhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Showing 10 of 17 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

incomplete Freund's adjuvant

EEastern Cooperative Oncology Group

Trodelvy

Halaven

Adriamycin

GGynecologic Oncology Group

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Prolia

Cymbalta

Alnylam Pharmaceuticals

Recentin

NNational Cancer Institute (NCI)

Spravato

Avastin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Neuroendocrine Carcinoma

NCT06202066

Clinical

Trials by Indication[1]

Melanoma20 trials

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Completed·CCraig L Slingluff, Jr·Phase 1/2·NCT00118274·170 enrolled

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Completed·UUniversity of Virginia·Phase 2·NCT00089206·7 enrolled

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Completed·UUniversity of Southern California·Phase 2·NCT00085189·42 enrolled

Show 17 more trials

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00089063·40 enrolled

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00706992·50 enrolled

Vaccine Therapy in Treating Patients With Advanced Melanoma

Completed·CCraig L Slingluff, Jr·Phase 1·NCT00705640·45 enrolled

Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003362

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Completed·CCraig L Slingluff, Jr·Phase 1·NCT00118313

Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00077532·179 enrolled

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

Completed·UUniversity of Southern California·Phase 1·NCT00025181·19 enrolled

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Terminated·UUniversity of Southern California·Phase 1·NCT00005841·15 enrolled

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

Completed·NNational Cancer Institute (NCI)·N/A·NCT00006243·30 enrolled

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

Completed·UUniversity of Southern California·Phase 2·NCT00003274·48 enrolled

Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00357461

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Completed·UUniversity of Virginia·Phase 2·NCT00003222·40 enrolled

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00032045

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

Completed·UUniversity of Southern California·Phase 2·NCT00003339·48 enrolled

Vaccine Therapy in Treating Patients With Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00020358

Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Completed·CCraig L Slingluff, Jr·Phase 2·NCT00089193

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Completed·UUniversity of Southern California·Phase 2·NCT00031733·60 enrolled

Metastatic Melanoma16 trials

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019721

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00091104·136 enrolled

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00071981·175 enrolled

Show 13 more trials

LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00295958·26 enrolled

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

Completed·PProvidence Cancer Center, Earle A. Chiles Research Institute·Phase 1·NCT00091143·20 enrolled

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00022438

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00303836·58 enrolled

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019487

Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00091338

Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00079144

Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00006385

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1/2·NCT00062036·33 enrolled

Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019383

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019994

Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00072085

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·UUniversity of Illinois at Chicago·Phase 2·NCT00003568

Breast Cancer2 trials

Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer

Completed·—·Phase 1·NCT00079157·28 enrolled

Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

Completed·MMayo Clinic·Phase 1·NCT00640861·45 enrolled

Non-Small Cell Lung Cancer2 trials

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00398138·22 enrolled

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Unknown status·EEpimmune·Phase 2·NCT00104780

Prostate Cancer2 trials

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00109811·32 enrolled

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00030602

11 more indications

Primary Peritoneal Cancer1 trial

Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer

Completed·UUniversity of Virginia·Phase 1·NCT00091273·9 enrolled

Adjuvant1 trial

Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00381875·40 enrolled

Neuroendocrine Carcinoma1 trial

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Recruiting·RRoswell Park Cancer Institute·Phase 2·NCT06202066·60 enrolled

Multiple Myeloma1 trial

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Active, not recruiting·RRoswell Park Cancer Institute·Phase 1·NCT02334865·18 enrolled

Metastatic Neuroendocrine Tumor1 trial

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Completed·RRoswell Park Cancer Institute·Phase 1·NCT03879694·19 enrolled

Ovarian Cancer1 trial

p53 Vaccine for Ovarian Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00001827·21 enrolled

Metastatic Cancer1 trial

Vaccine Therapy in Treating Patients With Metastatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00021164

Renal Cell Carcinoma1 trial

Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00001703·6 enrolled

Fallopian Tube Cancer1 trial

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT01673217·18 enrolled

Myelodysplastic Syndrome1 trial

Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

Unknown status·TThe Vaccine Company·Phase 2·NCT00513578·30 enrolled

Gastrointestinal1 trial

Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract

Terminated·TThe University of Texas Medical Branch, Galveston·Phase 2·NCT00012246·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 53 trial records for incomplete Freund's adjuvant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — incomplete Freund's adjuvant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for incomplete Freund's adjuvant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eastern Cooperative Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: EEastern Cooperative Oncology Group

Related News